- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169360
Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder (SEARCH)
January 25, 2021 updated by: Sarah Kattakuzhy, University of Maryland, Baltimore
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy.
Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months.
Subjects will subsequently be followed for an additional one month post treatment.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy.
At screening, after providing consent, participants will be evaluated to ensure criteria for opioid use disorder by DSM V criteria is met, and whether the subject is receiving opioid agonist therapy will be determined.
Participants will undergo a medical evaluation (including medical history, laboratory tests and EKG evaluation) to establish baseline medical and psychiatric diagnosis in order to ensure safety of participation.
Once enrollment criteria are met, patients will be randomized in a blinded fashion to ANS-6637 or placebo, stratified by site and form of opioid agonist therapy.
On Day 0, patients will be initiated on ANS-6637 vs. placebo according to randomization group.
Subjects will be seen twice per week for two weeks, followed by weekly for two weeks, and then monthly for two months.
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have the ability to understand and must personally sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- Must be between 18 and 65 years of age, inclusive.
- Must have the diagnosis of opioid use disorder by DSM (Diagnostic and Statistical Manual of Mental Disorders) V criteria of at least mild severity
- Must have a total score of 9 or greater (out of a total of 30) on the Opioid Craving Scale at screening
- If on opioid agonist therapy, must be on Opioid Agonist Therapy (OAT) medication for a minimum of six months prior to screening.
- If on medication for depression or anxiety, must be on a stable dose for a minimum of two months prior to screening.
- Must be able to take oral medication and be willing to adhere to the medication regimen
- Must agree to utilize the "AI Cure" platform, either on their personal phone or on a supplied device, for both daily video adherence monitoring as well as daily questionnaires for the entire study duration.
- Male subjects must refrain from sperm donation throughout the study period, and continuing for at least 90 days following the last dose of study drug.
- Subjects must refrain from blood donation throughout the study period, and continuing for at least 30 days following the last dose of study drug.
- Must be willing to comply with contraception guidelines: The fetal risks associated with ANS-6637 are not known, but pre-clinical animal data demonstrate some risk. Subjects must agree not to become pregnant or impregnate a female. Females of childbearing potential must have a pregnancy test at screening and baseline (Day 0). If pregnancy occurs or is suspected to occur, study staff must be notified immediately. For the duration of the study, subjects or female partners of childbearing potential must use one of the following, unless she is surgically sterile, post-menopausal, or partner is surgically sterile: oral contraceptives (OCP), contraceptive sponge, patch double barrier (diaphragm + spermicide or condom + spermicide), intrauterine device (IUD), etonogestrel implant, injection, hormonal vaginal contraceptive ring or complete abstinence
- Must be willing and able to comply with all study requirements and plan to attend all clinic visits.
Exclusion Criteria:
A subject will be ineligible for this study if 1 or more of the following criteria are met:
- Clinically significant AND grade 2 or higher abnormal laboratory values at screening, as determined by principal investigator
- Aspartate transaminase (AST) or Alanine transaminase (ALT) > 2.5 x upper limit of normal or total bilirubin > 1.6 x the upper limit of normal
- Creatinine clearance < 60 mL/min/1.73m2 by Chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) Score.
- Personal or family history of Parkinson's Disease
- Diagnosed major depression AND with current self-reported depression episode
- Diagnosed generalized anxiety disorder AND with current self-reported uncontrolled anxiety
- Current self-reported suicidal ideation
- Diagnosed liver disease, including untreated chronic Hepatitis C (defined as detectable Hepatitis C RNA), Hepatitis B (defined as positive HBsAg), and/or cirrhosis (defined as Fibrosis (FIB)-4 > 3.25 AND confirmed by Fibroscan or Fibrosure)
- Diagnosed Human Immunodeficiency Virus (HIV) AND detectable viral load > 40 copies/mL
- Diagnosed moderate or serious dementia Taking any of the following medications in the last 6 months: dopamine agonist, dopamine antagonist, anti-psychotic, anti-convulsant (except for benzodiazepines and gabapentin) or barbiturate
- Inability to obtain venous access for sample collection.
- Had a prior history of any severe adverse reactions to ethanol [e.g., flushing (noticeable redness of the neck or throat) and/or increased heart rate (subject reports sensation of increased heart rate or palpitations) after drinking alcohol].
- Known hypersensitivity to formulation excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc.
- Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to screening
- Have any unresolved legal issues that could jeopardize continuation or completion of the study, at the discretion of the principal investigator
- Have any serious or active medical, surgical, or psychiatric conditions which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
- Are unable to comply with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ANS-6637
ANS-6637 600mg once daily for 12 weeks
|
White, oblong 300 mg tablet
|
Placebo Comparator: Placebo arm
Placebo 600 mg once daily for 12 weeks
|
White, oblong 300 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Grade 3-4 events, Grade 2 Significant event
Time Frame: 16 weeks
|
The number of Grade 3-4 adverse events, as defined by the Division of AIDS (DAIDS) Toxicity Table Version 2.1, July, 2017 as well as the number of Grade 2 events requiring medication interruption or deemed clinically significant by a study investigator
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine Drug Screen
Time Frame: 16 weeks
|
Percentage opioid free period by urine drug screen
|
16 weeks
|
Opioid Craving
Time Frame: 16 weeks
|
Opioid craving will be assessed using the Opioid Craving scale questionnaire.
The questionnaire consists of three questions and each of these questions has a minimum value of 0 and a maximum value 10.
A score of 0 on each question is the best outcome; a score of 10 on each question is the worst outcome.
|
16 weeks
|
Opioid Agonist Therapy (OAT) concentration
Time Frame: 16 weeks
|
Serum concentration of buprenorphine or methadone
|
16 weeks
|
Self reported description of drug use (Self-reported frequency/quantity/mode of opioid use, self-reported use of other drugs, overdose and overdose death)
Time Frame: 16 weeks
|
Self-reported frequency/quantity/mode of opioid use as well as self-reported use of other drugs will be gathered using the Drug Use Survey.
Subjects will indicate frequency of opioid use by documenting the number of times they used an opioid during a given day.
The quantity of opioids used will be determined by the dollar amount of opioids the subject reports they have consumed during that day.
Subjects will also report mode of opioid use by indicating whether they are using opioids via injection, skin popping, snorting or oral.
The Drug Use Survey will also ask subjects to report incidence of use of non-opioid substances.
Incidence of overdose will be captured with the Naloxone questionnaire which asks, "since you last visit, have you experienced an overdose?".
Incidence of overdose death will measured by the number of medical examiner confirmed deaths of study participants with cause of death listed as "overdose related to an opioid".
|
16 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Darke HIV Risk Taking Behavior Survey Score
Time Frame: 16 weeks
|
The Darke HIV Risk Taking Behavior Questionnaire will be administered to assess subject's self-reported risk taking behaviors.
Total scores on the test range from 0 to 55, with higher scores indicating a greater degree of risk-taking behavior.
|
16 weeks
|
Change in HIV Test Result
Time Frame: 16 weeks
|
An HIV test (fourth generation antigen/antibody test) will be administered and the results are reported as either positive or negative.
|
16 weeks
|
Change in Hepatitis C (HCV) RNA result
Time Frame: 16 weeks
|
A Hepatitis C (HCV) RNA test will be administered.
This test measures the quantity of detectable RNA which is measured in IU/ml.
|
16 weeks
|
Change in appetite
Time Frame: 16 weeks
|
Self reported changes in appetite will be captured by the Adverse Event Survey.
The survey will ask, "since your last visit, have you had an increase in your appetite or a decrease in your appetite?".
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sarah Kattakuzhy, MD, Institute of Human Virology at the University of Maryland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2021
Primary Completion (Actual)
January 12, 2021
Study Completion (Actual)
January 12, 2021
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
November 16, 2019
First Posted (Actual)
November 19, 2019
Study Record Updates
Last Update Posted (Actual)
January 28, 2021
Last Update Submitted That Met QC Criteria
January 25, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00088649
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The investigator will share de-identified data with approved outside collaborators under appropriate agreements, at the time of publication or shortly thereafter.
IPD Sharing Time Frame
Data will be available at the time of publication or shortly thereafter, and will be kept indefinitely.
IPD Sharing Access Criteria
Will be determined by Principal Investigator
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
Clinical Trials on ANS-6637
-
University of California, Los AngelesNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Amygdala NeurosciencesWithdrawn
-
National Institutes of Health Clinical Center (CC)National Institute of Allergy and Infectious Diseases (NIAID)CompletedOpiod Use DisorderUnited States
-
National Institute on Alcohol Abuse and Alcoholism...Terminated
-
Amygdala Neurosciences, Inc.CompletedHealthy VolunteersUnited States
-
Stanford UniversityWithdrawn
-
Centre Hospitalier Universitaire de Saint EtienneMinister of Youth Affairs and Sports, FranceCompletedFatigue | Training | AthletesFrance
-
University GhentUniversity of Utah; Universiteit AntwerpenRecruitingMuscle Tension Dysphonia | Functional Voice Disorder | Psychogenic Voice DisorderBelgium
-
China Medical University HospitalRecruiting
-
Abbott Medical DevicesCompletedEssential Tremor | Tremor | Action Tremor | Tremor, LimbUnited States
-
Abbott Medical DevicesWithdrawn